Cerebral Arterial Diseases

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Guerbet
GuerbetFrance - Villepinte
2 programs
2
DotaremPhase 31 trial
DotaremPhase 31 trial
Active Trials
NCT01010932Completed222Est. Dec 2010
NCT01012674Completed211Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GuerbetDotarem
GuerbetDotarem

Clinical Trials (2)

Total enrollment: 433 patients across 2 trials

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Start: Oct 2009Est. completion: Dec 2010222 patients
Phase 3Completed

Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Start: Oct 2009Est. completion: Dec 2010211 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space